Guo Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guo Bao has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Bin He
NHC Key Laboratory of Reproductive Health Engineering Technology Research, Department of Reproduction and Physiology, National Research Institute for Family Planning, Beijing 100081, China
1 shared publication Cancan Yao
Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China
1 shared publication- Changyong Zhang
Laboratory Animal Center, National Research Institute for Family Planning, Beijing 100081, China
1 shared publication - Derong Cao
South China University of Technology
1 shared publication - Eric Amador
School of CHIPS, Xian-Jiaotong Liverpool University, Suzhou 215123, China
1 shared publication - Guoda A
College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, China
1 shared publication
Latest Publications
- Open Access
Oral Supplementation with a Kudzu Root–Black Soybean Blend Attenuates Ovarian Dysfunction in Mice: Implications for Its Potential Use as a Dietary Supplement in Animal Nutrition
Kudzu (Pueraria lobata) root and black soybean (Glycine max) are plant-derived feed ingredients rich in bioactive phytochemicals, including puerarin, isoflavones, and anthocyanins. These compounds are recognized for their antioxidant and physiological regulatory properties, supporting their potential as dietary components in livestock nutrition. In this study, we evaluated the effects of the Pueraria–black soybean compound powder (KRBS) as a dietary additive on female reproductive performance using a cyclophosphamide (CTX)-induced ovarian dysfunction mouse model. The results showed that the high-dose KRBS group (CTX+H-KRBS) had a significantly increased ovarian index (p < 0.05), and all KRBS-treated groups recovered estrous cycle regularity (p < 0.01). Molecular analysis showed that KRBS significantly upregulated Amh expression (p < 0.05), decreased Bax expression, and increased Bcl2 expression, while reducing Esr1 and Vegfa expression in uterine tissues to levels comparable to those in the control group (p < 0.05). These molecular changes suggest that KRBS may alleviate CTX-induced ovarian dysfunction through the regulation of apoptosis-related gene expression, including Bax and Bcl2. These findings indicate that KRBS supplementation alleviates CTX-induced ovarian dysfunction through improvements in follicular development, reduction in serum FSH toward control levels, and apoptosis-related gene expression. These effects support the potential application of KRBS as a plant-based dietary supplement for preserving ovarian function.
Open AccessOral Supplementation with a Kudzu Root–Black Soybean Blend Attenuates Ovarian Dysfunction in Mice: Implications for Its Potential Use as a Dietary Supplement in Animal Nutrition
Kudzu (Pueraria lobata) root and black soybean (Glycine max) are plant-derived feed ingredients rich in bioactive phytochemicals, including puerarin, isoflavones, and anthocyanins. These compounds are recognized for their antioxidant and physiological regulatory properties, supporting their potential as dietary components in livestock nutrition. In this study, we evaluated the effects of the Pueraria–black soybean compound powder (KRBS) as a dietary additive on female reproductive performance using a cyclophosphamide (CTX)-induced ovarian dysfunction mouse model. The results showed that the high-dose KRBS group (CTX+H-KRBS) had a significantly increased ovarian index (p < 0.05), and all KRBS-treated groups recovered estrous cycle regularity (p < 0.01). Molecular analysis showed that KRBS significantly upregulated Amh expression (p < 0.05), decreased Bax expression, and increased Bcl2 expression, while reducing Esr1 and Vegfa expression in uterine tissues to levels comparable to those in the control group (p < 0.05). These molecular changes suggest that KRBS may alleviate CTX-induced ovarian dysfunction through the regulation of apoptosis-related gene expression, including Bax and Bcl2. These findings indicate that KRBS supplementation alleviates CTX-induced ovarian dysfunction through improvements in follicular development, reduction in serum FSH toward control levels, and apoptosis-related gene expression. These effects support the potential application of KRBS as a plant-based dietary supplement for preserving ovarian function.
- Open Access
- 1 June 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 36, 96-111
Combination of disulfiram and Copper−Cysteamine nanoparticles induces mitochondria damage and promotes apoptosis in endometrial cancer
Endometrial cancer (EC) stands as one of the most prevalent gynecological malignancies affecting women, with its incidence and disease-related mortality steadily on the rise. Disulfiram (DSF), an FDA-approved medication primarily used for treating alcohol addiction, has exhibited promising anti-tumor properties. Studies have revealed DSF's capacity for enhanced anti-tumor activity, particularly when combined with copper. The novel Copper-Cysteamine (CuCy) compound, Cu3Cl(SR)2 (R Created by potrace 1.16, written by Peter Selinger 2001-2019 CH2CH2NH2), showcases photodynamic effects and demonstrates significant anti-tumor potential under various conditions, including exposure to ultraviolet light, X-ray, microwave, and ultrasound. This study delves into exploring the synergistic anti-tumor effects and underlying mechanisms by utilizing copper-cysteamine in conjunction with DSF against endometrial cancer. The investigation involved comprehensive analyses encompassing in vitro experiments utilizing Ishikawa cells, in vivo studies, and transcriptomic analyses. Remarkably, the combined administration of both compounds at a low dose of 0.5 μM exhibited pronounced efficacy in impeding tumor growth, inhibiting blood vessel formation, and stimulating cell apoptosis. Notably, experiments involving transplanted tumors in nude mice vividly demonstrated the significant in vivo anti-tumor effects of this combination treatment. Detailed examination through transmission electron microscopy unveiled compelling evidence of mitochondrial damage, cellular swelling, and rupture, indicative of apoptotic changes in morphology due to the combined treatment. Moreover, transcriptomic analysis unveiled substantial downregulation of mitochondrial-related genes at the molecular level, coupled with a significant hindrance in the DNA repair pathway. These findings strongly suggest that the combined application of CuCy and DSF induces mitochondrial impairment in Ishikawa cells, thereby fostering apoptosis and ultimately yielding potent anti-tumor effects.
- 1 June 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 36, 96-111
Open AccessCombination of disulfiram and Copper−Cysteamine nanoparticles induces mitochondria damage and promotes apoptosis in endometrial cancer
Endometrial cancer (EC) stands as one of the most prevalent gynecological malignancies affecting women, with its incidence and disease-related mortality steadily on the rise. Disulfiram (DSF), an FDA-approved medication primarily used for treating alcohol addiction, has exhibited promising anti-tumor properties. Studies have revealed DSF's capacity for enhanced anti-tumor activity, particularly when combined with copper. The novel Copper-Cysteamine (CuCy) compound, Cu3Cl(SR)2 (R Created by potrace 1.16, written by Peter Selinger 2001-2019 CH2CH2NH2), showcases photodynamic effects and demonstrates significant anti-tumor potential under various conditions, including exposure to ultraviolet light, X-ray, microwave, and ultrasound. This study delves into exploring the synergistic anti-tumor effects and underlying mechanisms by utilizing copper-cysteamine in conjunction with DSF against endometrial cancer. The investigation involved comprehensive analyses encompassing in vitro experiments utilizing Ishikawa cells, in vivo studies, and transcriptomic analyses. Remarkably, the combined administration of both compounds at a low dose of 0.5 μM exhibited pronounced efficacy in impeding tumor growth, inhibiting blood vessel formation, and stimulating cell apoptosis. Notably, experiments involving transplanted tumors in nude mice vividly demonstrated the significant in vivo anti-tumor effects of this combination treatment. Detailed examination through transmission electron microscopy unveiled compelling evidence of mitochondrial damage, cellular swelling, and rupture, indicative of apoptotic changes in morphology due to the combined treatment. Moreover, transcriptomic analysis unveiled substantial downregulation of mitochondrial-related genes at the molecular level, coupled with a significant hindrance in the DNA repair pathway. These findings strongly suggest that the combined application of CuCy and DSF induces mitochondrial impairment in Ishikawa cells, thereby fostering apoptosis and ultimately yielding potent anti-tumor effects.